NCT00000298已完成2 期
Buprenorphine Combination Tablet Feasibility
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 1
- 主要终点
- Withdrawal symptoms
研究概览
简要总结
The purpose of this study is to determine target dose range of buprenorphine/naloxone combination tablet that provides therapeutic response in opiate addicts with low to moderate dependence, and to identify appropriate initial induction dose in opiate addicts with low to moderate dependence."
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males/Females ages 21-50, opiate dependence according to DSM-IV criteria, self-reported use within the last 30 days, agreeable to conditions of study and signed informed consent
排除标准
- •Psychiatric disorder that requires medication therapy, history of seizures, pregnant and/or nursing women, dependence on etoh or benzodiazepines or other sedative-hypnotics, acute hepatitis, other medical conditions that deem participation to be unsafe.
结局指标
主要结局
Withdrawal symptoms
Opiate use
Opiate craving
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1Opioid-Related DisordersHeroin DependenceNCT00000326University of Colorado, Denver
已完成
2 期
Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9Opioid-Related DisordersNCT00000344National Institute on Drug Abuse (NIDA)40
撤回
2 期
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3Heroin DependenceOpioid-Related DisordersNCT00000328University of Colorado, Denver
招募中
2 期
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use DisorderOpioid-use DisorderNCT05011266New York State Psychiatric Institute180
终止
2 期
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in SchizophreniaDiabetes Mellitus, Type 2ObesitySchizophreniaNCT03132571Yale University5